Targeting FLT3 by Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2017 May 13

PMID 28496177

Citations 32

Authors

L Chen

H Mao

J Zhang

J Chu

S Devine

M A Caligiuri

J Yu

Affiliations

Soon will be listed here.

Citing Articles

Development of multivalent CAR T cells as dual immunotherapy and conditioning agents.

Bubb Q, Balood M, Seir G, Swartzrock L, Haslett E, Ho K Mol Ther Oncol. 2025; 33(1):200944.

PMID: 40034967 PMC: 11872492. DOI: 10.1016/j.omton.2025.200944.

Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.

Nasiri F, Safarzadeh Kozani P, Salem F, Mahboubi Kancha M, Dashti Shokoohi S, Safarzadeh Kozani P Cancer Cell Int. 2025; 25(1):64.

PMID: 39994651 PMC: 11849274. DOI: 10.1186/s12935-025-03697-y.

Cell-Based Treatment in Acute Myeloid Leukemia Relapsed after Allogeneic Stem Cell Transplantation.

Canichella M, de Fabritiis P Biomedicines. 2024; 12(8).

PMID: 39200186 PMC: 11351713. DOI: 10.3390/biomedicines12081721.

Breaking Boundaries: Immunotherapy for Myeloid Malignancies.

Gavrilova T, Schulz E, Mina A Cancers (Basel). 2024; 16(16).

PMID: 39199554 PMC: 11352449. DOI: 10.3390/cancers16162780.

T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting.

Anderson G, Chapman M Mol Ther. 2024; 32(9):2856-2891.

PMID: 39095991 PMC: 11403239. DOI: 10.1016/j.ymthe.2024.07.028.

References

Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T . Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res. 2014; 20(15):3989-4000. PMC: 4119545. DOI: 10.1158/1078-0432.CCR-13-2510. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Grupp S, Kalos M, Barrett D, Aplenc R, Porter D, Rheingold S . Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16):1509-1518. PMC: 4058440. DOI: 10.1056/NEJMoa1215134. View

Gill S, Tasian S, Ruella M, Shestova O, Li Y, Porter D . Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014; 123(15):2343-54. PMC: 3983612. DOI: 10.1182/blood-2013-09-529537. View

Yu J, Mao H, Wei M, Hughes T, Zhang J, Park I . CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood. 2009; 115(2):274-81. PMC: 2808153. DOI: 10.1182/blood-2009-04-215491. View

Chu J, Deng Y, Benson D, He S, Hughes T, Zhang J . CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2013; 28(4):917-27. PMC: 3967004. DOI: 10.1038/leu.2013.279. View

Whitman S, Maharry K, Radmacher M, Becker H, Mrozek K, Margeson D . FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010; 116(18):3622-6. PMC: 2981481. DOI: 10.1182/blood-2010-05-283648. View

Whitman S, Archer K, Feng L, Baldus C, Becknell B, Carlson B . Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001; 61(19):7233-9. View

Dores G, Devesa S, Curtis R, Linet M, Morton L . Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2011; 119(1):34-43. PMC: 3251235. DOI: 10.1182/blood-2011-04-347872. View

10.

Han J, Chu J, Chan W, Zhang J, Wang Y, Cohen J . CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Sci Rep. 2015; 5:11483. PMC: 4496728. DOI: 10.1038/srep11483. View

11.

Rosnet O, Buhring H, Marchetto S, Rappold I, Lavagna C, Sainty D . Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996; 10(2):238-48. View

12.

Whitman S, Ruppert A, Radmacher M, Mrozek K, Paschka P, Langer C . FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2007; 111(3):1552-9. PMC: 2214747. DOI: 10.1182/blood-2007-08-107946. View

13.

Rappold I, Ziegler B, Kohler I, Marchetto S, Rosnet O, Birnbaum D . Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 1997; 90(1):111-25. View

14.

Ng S, Mitchell A, Kennedy J, Chen W, McLeod J, Ibrahimova N . A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016; 540(7633):433-437. DOI: 10.1038/nature20598. View

15.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

16.

Meshinchi S, Appelbaum F . Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009; 15(13):4263-9. PMC: 2716016. DOI: 10.1158/1078-0432.CCR-08-1123. View